Joe Vruwink

Claude for creative work and Autodesk involvement become a channel for new customer, new user acquisition

are they priced initially to drive adoption, so we might not see like a discrete uplift factor you're calling out in FY '27

Does that change anytime soon? Or are you actually seeing this whole strategy drive usage into your kind of mainstay products

Autodesk is ultimately having a role here

do you need the same level of prudence when you frame the forward outlook like you have been using

how does Autodesk ultimately think about the role it needs to play in AI?

is Autodesk, Inc. doing what it needs to be positioned when those prove viable?

some of the skill sets you are looking for and particularly, you know, Andy is gonna have a lot of new things he can undertake

you are assuming the agency change is about a 6-point impact on growth in the upcoming year

Do you think you're kind of outperforming there in that segment

Is that the right approach for Autodesk just given this point in time all the work you've done to build out the cloud platform

does that actually create the potential that things are better and that's why you're qualifying now the $2.05 billion

can you talk about the key contributors to the recurring improvement? And then just on the 20% or so of revs that come from upfront sources

I'm just wondering if you can maybe start to frame expectations for next year based on what you have in hand and it certainly seems like things are setting up well

Is this factoring into the bookings strength you've seen recently? And is it maybe leading to more spend or different spend with Cadence

your commentary and guidance strikes me as having greater visibility into strength during the second half of this year

how and when this becomes incremental for PTC. So maybe you can speak to like commercial strategy and pricing

are we maybe starting to see some that could prove more material in nature and this is gonna start to register in a more noticeable way on demand decisions

I was hoping to discuss the new packaging for Windchill that was introduced earlier in the month that strikes me as a pretty big simplification

the structure is mature ahead of needing to be positioned for maybe any benefit from renewed spending

I'm curious what they were in the quarter? And I think your definition excludes price

What's your take on this topic? And have you seen any changes year-to-date

Can you maybe put some guardrails in magnitude of what that could ultimately mean?

when would you expect to get to the point of quantifying what AI means for Roper at maybe a more precise level?

that seems like a very impressive number, just given the year ago period was an inflection higher in its own rate

do you maybe have a better sense of how that starts to impacts the P&L? How is it impacting like R&D spend?

are there any indications around the transition oriented revenues where maybe customer preference could slow if the macro remains uneasy

How would you frame a stress test around the nonrecurring elements of both AS and it could decline be possible there?

I would imagine you are run rating high-teens bookings going forward, but the last few quarters now have been pretty impressive

Does AI make it easier for others to come in and tackle those or do you think because you're the incumbent, you have the starting product focus

I wanted to go back to multiphysics fusion and is the greatest initial applicability really within sign offs

the quarter over quarter declined to $11 billion Is that as expected

Maybe can you walk through some of the biggest items in your mind that start to lift the growth profile in the EDA software business higher

would you expect some of these one-time cash items restructuring do those start to settle out of the model as we think forward into the out years

That midyear time frame, would you expect to know by then the magnitude of commitments you have in hand so that FY '27, you can maybe make the statement it will be back to mid-teens growth

Is that the appropriate time frame to fully enact the changes you're focused on and getting the business back on the track you believe is right

how much is IP coming down, how much does ANSYS add, China is a factor. Just anything there that can help get us all on the right baseline

Do you think the overall R&D landscape is maybe getting close to what you saw in the 2021, 2022 time frame

if the commerce department was nearing a point of restricting a broader swath of your sales into China, do you think you would have heard about it by now

Would you say that impacts your view at all that you expressed year ago about how AI could lift industry growth rates for EDA by about 200 basis points

I see in the 10-Q that backlog count position actually swung a bit more to current balances this quarter

Based on the $8.1 billion in backlog, another really strong quarter of bookings, it would seem like very high visibility on what the next 12 months may bring

the underlying growth of 11.5% to 12.5%. I think that's maybe a point below the starting ranges you've been using over recent history

Are there things like service center or campaign manager that are adding incrementally to the forecast

I wanted to ask if Veeva is starting to see some programs funded maybe in the name of AI readiness

what stood out to you both in terms of, I'll say, reception, but then also maybe any pushback

how should we think about all of that netting together

is quality maybe factoring more into the five-year plan than you thought perhaps a year ago

Do you actually think the bigger consequence is maybe more strategic in that Vault has developed such robust architecture

would you expect to see those weaken at this point if there were maybe looming signs of pressure for the second half

Have the reasons customers cited behind migration decisions changed at all

I think there's maybe a trend in the large pharma community to perhaps reduce procurement risk and consolidate around strategic vendors

I wanted to see if these are maybe similar in scope to how Veeva has come to work with the likes of Merck and BI